May 17, 2023 / 12:30PM GMT
Brian Abrahams - RBC Capital Markets - Analyst
All right. Good morning, everyone. I'm Brian Abrahams, one of the senior biotech analysts here at RBC. We're really pleased to have our next presenting company, 89bio represented by their CFO, Ryan Martins. Ryan, thanks so much for joining us today.
Ryan Martins - 89bio, Inc. - CFO
Thanks, Brian. Excited to be here, and thanks for the invitation.
Brian Abrahams - RBC Capital Markets - Analyst
Of course. So maybe let's start bigger picture. I was wondering if you could maybe catch everybody up on the latest status of pegozafermin, the key findings from the recent Phase 2b study you reported -- Phase 2b studies you reported in NASH and SHTG and the overall next steps? And then would love to dive into some of those details after.
Ryan Martins - 89bio, Inc. - CFO
Yeah. Perfect. Just to make sure everyone's familiar with the company, we are a company that's late clinical stage that's focused on developing drugs for liver and cardio
89Bio Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers